Pharmacokinetics of Rifabutin in HIV-infected Patients with or Without Wasting Syndrome

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1999 Dec 14

PMID 10594472

Citations 6

Authors

G Gatti

A Di Biagio

C R De Pascalis

M Guerra

M Bassetti

D Bassetti

Affiliations

Soon will be listed here.

Abstract

Aims: The purpose of the study was to compare the pharmacokinetic parameters of rifabutin obtained in a group of patients without wasting syndrome (NWS) with those obtained in a group with wasting syndrome (WS).

Methods: A single dose of 300 mg rifabutin was administered in the fasting state to the patients in both study groups and blood samples were scheduled to be collected at the following times: 0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72 and 96 h following administration. Data were analysed using noncompartmental methods. The pharmacokinetic parameters of rifabutin in patients with and without wasting syndrome were compared using the Mann-Whitney U-test.

Results: Cmax was 0.34+/-0. 14 mg l-1 in NWS patients and 0.55+/-0.16 mg l-1 (P=0.01) in patients with WS. tmax was 4.2+/-1.5 and 3.3+/-2.3 h (P=0.17) in NWS and WS patients, respectively. The AUCs were similar in the two study groups. V/F was 2905+/-1646 l in NWS patients and 1701+/-492 l (P=0.07) for the WS group. These differences are less pronounced following normalization of V/F to patients body weight (43.7+/-20.1 vs 35.4+/-10.3 l kg-1 ). t1/2,lambdaz tended to be shorter in patients with WS (31.4+/-12.9 vs 46.0+/-23.5 h, P=0.12).

Conclusions: Our study suggests that the pharmacokinetics of rifabutin in patients with wasting syndrome are not altered to a degree that is clinically important.

Citing Articles

Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.

Wasserman S, Antilus-Sainte R, Abdelgawad N, Odjourian N, Cristaldo M, Dougher M Antimicrob Agents Chemother. 2024; 68(8):e0078324.

PMID: 39028192 PMC: 11304741. DOI: 10.1128/aac.00783-24.

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.

Verrest L, Wilthagen E, Beijnen J, Huitema A, Dorlo T Clin Pharmacokinet. 2021; 60(9):1149-1169.

PMID: 34060020 PMC: 8545752. DOI: 10.1007/s40262-021-01031-z.

Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Infections.

Phillips M, Wald-Dickler N, Loomis K, Luna B, Spellberg B Open Forum Infect Dis. 2020; 7(11):ofaa460.

PMID: 33204754 PMC: 7651144. DOI: 10.1093/ofid/ofaa460.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Hennig S, Svensson E, Niebecker R, Fourie P, Weiner M, Bonora S J Antimicrob Chemother. 2016; 71(5):1330-40.

PMID: 26832753 PMC: 4830412. DOI: 10.1093/jac/dkv470.

Pharmacokinetics of drugs in cachectic patients: a systematic review.

Trobec K, Kos M, von Haehling S, Springer J, Anker S, Lainscak M PLoS One. 2013; 8(11):e79603.

PMID: 24282510 PMC: 3835942. DOI: 10.1371/journal.pone.0079603.

References

Eberts T, Sample R, Glick M, Ellis G . A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol. Clin Chem. 1979; 25(8):1440-3. View

Choudhri S, Hawken M, Gathua S, Minyiri G, Watkins W, Sahai J . Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis. 1997; 25(1):104-11. DOI: 10.1086/514513. View

Gillin J, Shike M, ALCOCK N, Urmacher C, Krown S, Kurtz R . Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 102(5):619-22. DOI: 10.7326/0003-4819-102-5-619. View

Lake-Bakaar G, Tom W, Gupta N, Beidas S, Elsakr M, STRAUS E . Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988; 109(6):471-3. DOI: 10.7326/0003-4819-109-6-471. View

Ullrich R, Zeitz M, Heise W, Lage M, Hoffken G, Riecken E . Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med. 1989; 111(1):15-21. DOI: 10.7326/0003-4819-111-1-15. View

Harriman G, Smith P, Horne M, Fox C, Koenig S, Lack E . Vitamin B12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1989; 149(9):2039-41. View

Kotler D, Tierney A, Brenner S, Couture S, Wang J, Pierson Jr R . Preservation of short-term energy balance in clinically stable patients with AIDS. Am J Clin Nutr. 1990; 51(1):7-13. DOI: 10.1093/ajcn/51.1.7. View

Connolly G, Forbes A, Gazzard B . Investigation of seemingly pathogen-negative diarrhoea in patients infected with HIV1. Gut. 1990; 31(8):886-9. PMC: 1378616. DOI: 10.1136/gut.31.8.886. View

Melchior J, Salmon D, Rigaud D, Leport C, Bouvet E, Detruchis P . Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr. 1991; 53(2):437-41. DOI: 10.1093/ajcn/53.2.437. View

10.

Ehrenpreis E, Gulino S, Patterson B, CRAIG R, Yokoo H, Atkinson Jr A . Kinetics of D-xylose absorption in patients with human immunodeficiency virus enteropathy. Clin Pharmacol Ther. 1991; 49(6):632-40. DOI: 10.1038/clpt.1991.80. View

11.

Smith P, Quinn T, Strober W, Janoff E, Masur H . NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med. 1992; 116(1):63-77. DOI: 10.7326/0003-4819-116-1-63. View

12.

Macnab K, Gill M, Sutherland L, de Boer Visser N, Church D . Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother. 1993; 31(3):421-8. DOI: 10.1093/jac/31.3.421. View

13.

Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J . Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993; 37(5):1137-43. PMC: 187917. DOI: 10.1128/AAC.37.5.1137. View

14.

Gordon S, Horsburgh Jr C, Peloquin C, Havlik Jr J, Metchock B, Heifets L . Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis. 1993; 168(6):1559-62. DOI: 10.1093/infdis/168.6.1559. View

15.

Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller M . Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 8(3):239-46. DOI: 10.1097/00042560-199503010-00004. View

16.

Chin T, Vandenbroucke A, Fong I . Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995; 39(1):28-33. PMC: 162479. DOI: 10.1128/AAC.39.1.28. View

17.

Chlebowski R, Grosvenor M, Lillington L, Sayre J, BEALL G . Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc. 1995; 95(4):428-32; quiz 433-5. DOI: 10.1016/S0002-8223(95)00115-8. View

18.

Tett S, Moore S, Ray J . Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother. 1995; 39(8):1835-41. PMC: 162835. DOI: 10.1128/AAC.39.8.1835. View

19.

Bjarnason I, Sharpstone D, Francis N, Marker A, Taylor C, Barrett M . Intestinal inflammation, ileal structure and function in HIV. AIDS. 1996; 10(12):1385-91. DOI: 10.1097/00002030-199610000-00011. View

20.

Kotler D, Gaetz H, Lange M, Klein E, Holt P . Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 101(4):421-8. DOI: 10.7326/0003-4819-101-4-421. View